Hepion Pharmaceuticals Begins Wind-Down Activities in ASCEND-NASH P-IIb Study

Share this
Hepion Pharmaceuticals

Hepion Pharmaceuticals Begins Wind-Down Activities in ASCEND-NASH P-IIb Study


  • Hepion has begun wind-down activities of ASCEND-NASH P-IIb study, to evaluate safety and efficacy of Rencofilstat for 12 mos. to treat non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
  • ASCEND-NASH, a P-IIb study (estimated enrolment 336) started in Aug'22 was paused in Apr'23, with 151 randomized patients. Until now, around 80 patients have completed their Day 365 visits and evaluated for safety and efficacy. Additional, 40 patients will provide substantial safety data for evaluation; patients will be added to company’s existing safety database
  • Rencofilstat received Fast Track designation (FTD) from US FDA for NASH in Nov'21, and Orphan Drug designation (ODD) for HCC in Jun'22

Ref: Hepion Pharmaceuticals | Image: Hepion Pharmaceuticals

Related News:- Sanofi Features P-IIb (STREAM-AD) Study Data of Amlitelimab for the Treatment of Atopic Dermatitis at AAD’24

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions